PUBLISHER: KBV Research | PRODUCT CODE: 1483523
PUBLISHER: KBV Research | PRODUCT CODE: 1483523
The North America Artificial Intelligence (AI) in Healthcare Market would witness market growth of 40.4% CAGR during the forecast period (2024-2031).
The US market dominated the North America Artificial Intelligence (AI) in Healthcare Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $65,967.2 million by 2031. The Canada market is experiencing a CAGR of 43.6% during (2024 - 2031). Additionally, The Mexico market would exhibit a CAGR of 42.4% during (2024 - 2031).
AI algorithms can analyze medical images such as X-rays, CT scans, and MRIs to assist radiologists in detecting abnormalities, tumors, fractures, and other conditions. These algorithms can help improve diagnostic accuracy and speed up the interpretation process. AI can automate the analysis of tissue samples and pathology slides, aiding pathologists in diagnosing diseases like cancer. AI-powered image analysis can detect subtle patterns and anomalies that human observers may miss.
Drug discovery can be improved by AI systems' ability to assess molecular structures and forecast how various compounds interact with biological targets. Virtual screening expedites the identification of promising drug candidates, reducing time and cost over traditional procedures. AI can analyze large biological and clinical data sets to identify existing medications that have the potential to be repurposed for novel therapeutic applications. This method can speed up the development of treatments for various diseases by utilizing existing drug molecules with known safety profiles.
AI algorithms can analyze vast amounts of biological data, including genomic information, protein structures, and chemical compounds, to identify potential drug candidates more quickly and efficiently than traditional methods in Mexico. This acceleration of the drug discovery process is particularly valuable in addressing urgent medical needs and emerging diseases in Mexico. AI facilitates drug repurposing by analyzing existing drug libraries and identifying potential new uses for approved drugs in Mexico. Additionally, AI algorithms can predict synergistic interactions between drugs and identify optimal combinations for combination therapies, enhancing treatment efficacy and overcoming drug resistance in Mexico. Hence, the factors mentioned above will drive the regional market growth.
Based on Offering, the market is segmented into Software, Hardware (Processors, Memory, and Network), and Services. Based on Software Platform, the market is segmented into Application Program Interface (API), and Machine Learning Framework. Based on Software Solution, the market is segmented into On-premise, and Cloud. Based on Technology, the market is segmented into Machine Learning, Natural Language Processing, Context-aware Computing, and Computer Vision. Based on End-use, the market is segmented into Healthcare Providers, Healthcare Companies, Healthcare Payers, Patients, and Others. Based on Application, the market is segmented into Patient Data & Risk Analysis, Virtual Assistants, Wearables, Medical Imaging & Diagnostics, Cybersecurity, Mental Health, In-Patient Care & Hospital Management, Precision Medicine, Drug Discovery & Development, Lifestyle Management & Remote Patient Monitoring, Healthcare Assistance Robots, Research, Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
List of Key Companies Profiled
North America Artificial Intelligence (AI) in Healthcare Market Report Segmentation
By Offering
By Technology
By End-use
By Application
By Country